Exchange Traded Concepts LLC Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Exchange Traded Concepts LLC cut its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 32.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,311 shares of the company’s stock after selling 3,934 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Tyra Biosciences were worth $195,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. purchased a new position in Tyra Biosciences in the first quarter valued at about $977,000. Vanguard Group Inc. grew its stake in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after acquiring an additional 140,833 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after acquiring an additional 145,346 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new stake in shares of Tyra Biosciences during the second quarter valued at about $3,047,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TYRA. Piper Sandler began coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Oppenheimer lifted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright lifted their price target on Tyra Biosciences from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $22.00 to $31.00 in a research note on Friday. Finally, Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $31.00.

Tyra Biosciences Stock Up 3.8 %

Shares of NASDAQ TYRA opened at $28.37 on Tuesday. The firm’s 50-day moving average price is $22.48 and its two-hundred day moving average price is $19.60. Tyra Biosciences, Inc. has a 52-week low of $10.38 and a 52-week high of $28.81. The stock has a market capitalization of $1.50 billion, a P/E ratio of -16.79 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Todd Harris sold 10,092 shares of Tyra Biosciences stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96. Following the sale, the chief executive officer now owns 1,479,528 shares of the company’s stock, valued at approximately $35,701,010.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 42,319 shares of company stock valued at $1,050,330 over the last quarter. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.